- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04761614
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
A Phase I Study of Riluzole in Combination With mFOLFOX6/Bevacizumab in Patients With Metastatic Colorectal Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. Characterize the safety and toxicity of riluzole in combination with modified (m) leucovorin calcium, fluorouracil, and oxaliplatin (FOLFOX) 6/bevacizumab and determine the recommended phase II dose (RP2D) of riluzole in combination with mFOLFOX6/bevacizumab in patients with metastatic colorectal cancer.
SECONDARY OBJECTIVE:
I. Determine the pharmacokinetics of riluzole in patients with metastatic CRC.
EXPLORATORY OBJECTIVES:
I. Assess the efficacy of the combination treatment. II. Determine the effect of riluzole in downstream GRM3 signaling by immunofluorescent staining of phosphorylated (p)AKT and pCREB in pre- and post-treatment tumor tissues.
III. Assess FCGRT/FcRn expression, bevacizumab pharmacokinetics, inflammatory cytokines, and cachexia associated factors as early biomarkers for resistance to therapy.
IV. Assess cytotoxic T cells in peripheral blood to evaluate the immunomodulatory effect of this therapy.
OUTLINE: This is a dose-escalation study of riluzole.
Patients receive riluzole orally (PO) twice daily (BID) on days 1-14. Patients also receive oxaliplatin via intravenous piggyback (IVPB) over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via intravenous (IV) push over 5 minutes and then IV continuously over 46 hours on days 1-2. Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up for 30 days.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with metastatic colorectal cancer, who are appropriate candidates to receive mFOLFOX6/bevacizumab. Patients who progressed on FOLFOX-based regimen are allowed
- Willingness to undergo both pre-treatment and post-treatment tumor tissue biopsies (pre-treatment tumor tissue will be sent to pathology lab to confirm metastatic colorectal cancer as the standard of care)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Age >= 18 years
- Absolute neutrophil count >= (ANC) 1,500/ul
- Platelets >= 100,000/ul
- Hemoglobin >= 9 g/dl
- Serum total bilirubin < 1.5 x ULN
- Serum albumin >= 2.5 g/dl
- If no liver involvement, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN. If liver involvement, AST and ALT =< 3.0 x ULN
- Ability to understand and the willingness to sign a written informed consent document
- A male subject of fathering potential must use an adequate method of contraception to avoid conception throughout the study (and for up to 12 weeks after the last dose of study drug) to minimize the risk of pregnancy. If the partner is pregnant or breastfeeding, the subject must use a condom
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of study drug to minimize the risk of pregnancy. WOCBP must have a negative serum or urine pregnancy test within 72 hours before the start of the investigational product
Exclusion Criteria:
- Patients who are receiving any other investigational agents
- Patients with history of hepatitis B or C
- Patients with severe renal impairment (CrCl < 30 mL/min)
- Prior full field radiotherapy < 4 weeks or limited field radiotherapy < 2 weeks prior to first study drug administration. Patients with central nervous system (CNS) metastases may participate in this trial provided they are clinically stable. Patients who are < 1 month from radiation therapy must not be included
- Patients with existing grade 2 peripheral neuropathy
- Patients with a history of thrombotic or embolic events within the last six months such as a cerebrovascular accident (including transient ischemic attacks), pulmonary embolism or deep vein thrombosis
Cardiac conditions as follows:
- Active coronary artery disease, unstable or newly diagnosed angina or myocardial infarction less than 6 months prior to first study drug administration
- Class III-IV New York Heart Association (NYHA) congestive heart failure
- Uncontrolled hypertension (Systolic blood pressure [BP] > 150 mmHg and diastolic BP > 90 mmHg for 24 hours) despite optimal medical management
- Corrected QT (QTc) (Friderica) prolongation > 480 msec
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, cardiac arrhythmia, active bleeding diatheses, and psychiatric illness/social situations that would limit compliance with study requirements
- Major surgical procedure or significant traumatic injury less than 3 weeks or those who receive minor surgical procedures within 1 week from first dose of study drug administration
- Known inability to swallow capsules
- Inability to comply with study and/or follow-up procedures
- Pregnant women are excluded from this study. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother, breastfeeding should be discontinued
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (riluzole, mFOLFOX6, bevacizumab)
Patients receive riluzole PO BID on days 1-14.
Patients also receive oxaliplatin via IVPB over 2 hours, leucovorin calcium IVPB over 2 hours, and bevacizumab IVPB over 30 minutes on day 1 and fluorouracil via IV push over 5 minutes and then IV continuously over 46 hours on days 1-2.
Treatment repeats every 2 weeks for up to 8 cycles in the absence of disease progression or unacceptable toxicity.
|
Given IV
Other Names:
Given IVPB
Other Names:
Given IVPB
Other Names:
Given IVPB
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose limiting toxicities (DLTs)
Time Frame: Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days)
|
Will be defined by treatment related grade >= 4 adverse events or >= grade 3 alanine aminotransferase or aspartate aminotransferase elevation during the DLT period using the Common Terminology Criteria for Adverse Events version 5.0.
|
Up to 4 weeks (2 cycles of treatment) (1 cycle = 14 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetic (PK) profile of riluzole (Cmax)
Time Frame: Day 1 on cycle 1 (each cycle is 14 days)
|
K data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution.
The PK parameters including Cmax.
Peak Plasma Concentration (Cmax)
|
Day 1 on cycle 1 (each cycle is 14 days)
|
Pharmacokinetic (PK) profile of riluzole (AUC)
Time Frame: Day 1 on cycle 1 (each cycle is 14 days)
|
PK data analysis will utilize a nonlinear mixed effects approach whereby PK parameter estimates will be generated from the data, and 'dose day' will be evaluated as a covariate on clearance and volume of distribution.
The PK parameters including AUC.
Area under the plasma concentration versus time curve (AUC)
|
Day 1 on cycle 1 (each cycle is 14 days)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate (complete response + partial response)
Time Frame: Up to 112 days
|
Will be estimated along with exact 95% confidence interval.
|
Up to 112 days
|
Change in phosphorylated (p)AKT and pCREB levels
Time Frame: Up to 42 days (each cycle is 14 days)
|
Will be summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Up to 42 days (each cycle is 14 days)
|
Change in FCGRT/FcRn expression
Time Frame: Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
Will be assessed using peripheral blood and summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
Change in bevacizumab clearance (Cmax)
Time Frame: Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
Peak Plasma Concentration (Cmax)
|
Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
Change in bevacizumab clearance (AUC)
Time Frame: Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
Area under the plasma concentration versus time curve (AUC)
|
Day 1 of cycle 1, 3, 5, 7 (each cycle is 14 days)
|
interleukin 6
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
leukemia inhibitory factor
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Necrosis factor alpha
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Interferon gamma
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
C-reactive protein
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
ferritin
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
metalloproteinases 1
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Cytokines
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
body weight
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Will include body weight and summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
skeletal muscle index
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Will include skeletal muscle index and summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
body serum albumin
Time Frame: Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Will include body serum albumin and summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Day 1 of cycle 1 and day 1 of cycle 7 (each cycle is 14 days)
|
Change in levels of circulating cytotoxic T cells
Time Frame: Day 1 of Cycle 1,3,5,7 (each cycle is 14 days)
|
Will be assessed using peripheral blood mononuclear cells and summarized using mean +/- standard error of mean, range, and median at each time point.
Graphical analyses will be largely used to assess potential patterns and relationships.
|
Day 1 of Cycle 1,3,5,7 (each cycle is 14 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ning Jin, MD, Ohio State University Comprehensive Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Neuroprotective Agents
- Protective Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Anticonvulsants
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Antidotes
- Vitamin B Complex
- Hematinics
- Antibodies
- Fluorouracil
- Oxaliplatin
- Immunoglobulins
- Bevacizumab
- Leucovorin
- Calcium
- Levoleucovorin
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Folic Acid
- Calcium, Dietary
- Immunoglobulin G
- Endothelial Growth Factors
- Riluzole
Other Study ID Numbers
- OSU-20096
- NCI-2021-00018 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Carcinoma
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Metastatic Malignant Neoplasm in the Lung | Resectable Colorectal CarcinomaUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Cholangiocarcinoma | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colon Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
Clinical Trials on Fluorouracil
-
The Netherlands Cancer InstituteCompleted
-
Sun Yat-sen UniversityZhejiang Cancer Hospital; Fudan University; Peking University Cancer Hospital... and other collaboratorsUnknownNasopharyngeal CarcinomaChina
-
CStone PharmaceuticalsActive, not recruitingUnresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityUnknown
-
Actavis Inc.CompletedActinic KeratosisUnited States
-
The Netherlands Cancer InstituteCompleted
-
Hui ting Xu,MDJiangsu HengRui Medicine Co., Ltd.UnknownClinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer PatientsMetastatic Colorectal CancerChina
-
Kansai Hepatobiliary Oncology GroupUnknownHepatocellular CarcinomaJapan
-
Hokkaido Gastrointestinal Cancer Study GroupHokkaido University HospitalCompleted
-
The Cleveland ClinicNational Cancer Institute (NCI)TerminatedActinic Keratosis | Organ or Tissue Transplant; ComplicationsUnited States